Eric Lander, director of the Broad Institute of MIT and Harvard, has received the 2007 Society for Biomolecular Sciences Achievement Award for Innovation in HTS, the group said last week.
The Award recognizes “outstanding achievements in research, innovation, groundbreaking foundation or seminal contributions that have proven to be broadly applicable to biomolecular sciences or pharmaceutical/agricultural lead discovery.”
Lander will receive his award during a presentation at the Society for Biomolecular Science’s 13th Annual Conference & Exhibition in Montreal, Canada, which will be held on April 15-19. He will also receive a $5,000 honorarium.
CytRx this week said its RNAi drugs subsidiary, RXi Pharmaceuticals, has appointed a five-member board of directors.
Joining the new company’s board is Mark Ahn, who is currently president, CEO, and director of Hana Biosciences. Before joining Hana, Ahn was vice president of hematology and corporate officer at Genentech. He has also held various positions at Amgen and Bristol-Myers Squibb.
Stephen Galliker has also been named to RXi’s board. Galliker is currently executive vice president of finance and administration, as well as CFO, at Dyax. Before joining this company, he held various senior management positions, including CFO, at Excel Switching.
RXi has also appointed Sanford Hillsberg, a managing partner at the law firm Troy & Gould Professional, to its board.
Hillsberg is also the founder, director, and corporate secretary of ImmunoCellular Therapeutics, and is a director of Tempra Technology, a thermal research and development firm. He previously was a director and vice president of Medco Research.
RXi has also named CytRx President and CEO Steven Kriegsman and RXi President and CEO Tod Woolf to its board.
Alnylam Pharmaceuticals said that its director of research, Rachel Meyers, has been named one of R&D Directions’ “Top 20 Most Notable People in R&D.”
According to Alnylam, Meyers has also been named one of Mass High Tech’s “Women to Watch.”